- Home
- ENLV vs NRSN Comparison
ENLV vs NRSN Comparison
Compare ENLV & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- NRSN
- Stock Information
- Founded
- ENLV 2005
- NRSN 2017
- Country
- ENLV Israel
- NRSN Israel
- Employees
- ENLV N/A
- NRSN N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ENLV Health Care
- NRSN Health Care
- Exchange
- ENLV Nasdaq
- NRSN Nasdaq
- Market Cap
- ENLV 26.6M
- NRSN 29.8M
- IPO Year
- ENLV 1995
- NRSN 2021
- Fundamental
- Price
- ENLV $0.98
- NRSN $0.98
- Analyst Decision
- ENLV Strong Buy
- NRSN Buy
- Analyst Count
- ENLV 2
- NRSN 2
- Target Price
- ENLV $10.00
- NRSN $14.00
- AVG Volume (30 Days)
- ENLV 124.2K
- NRSN 202.0K
- Earning Date
- ENLV 11-28-2025
- NRSN 12-17-2025
- Dividend Yield
- ENLV N/A
- NRSN N/A
- EPS Growth
- ENLV N/A
- NRSN N/A
- EPS
- ENLV N/A
- NRSN N/A
- Revenue
- ENLV N/A
- NRSN N/A
- Revenue This Year
- ENLV N/A
- NRSN N/A
- Revenue Next Year
- ENLV N/A
- NRSN N/A
- P/E Ratio
- ENLV N/A
- NRSN N/A
- Revenue Growth
- ENLV N/A
- NRSN N/A
- 52 Week Low
- ENLV $0.81
- NRSN $0.80
- 52 Week High
- ENLV $2.10
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- ENLV 37.32
- NRSN 37.32
- Support Level
- ENLV $1.03
- NRSN $0.89
- Resistance Level
- ENLV $1.05
- NRSN $0.97
- Average True Range (ATR)
- ENLV 0.04
- NRSN 0.07
- MACD
- ENLV -0.00
- NRSN -0.01
- Stochastic Oscillator
- ENLV 6.47
- NRSN 26.22
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.